论文部分内容阅读
HER-2/neu原癌基因在20％～30％的浸润性乳腺癌中存在扩增和过度表达。但是对HER-2/neu超时表达变化与肿瘤演进或不同转移位点表达的异源性程度的研究非常局限,为了确定原发肿瘤中HER-2/neu蛋白含量是否不同于浸润癌,浸润癌中HER-2/neu表达是否存在异源性,作者用免疫过氧化物酶技术和抗HER-2/neu基因185-kD蛋白产物(p185)单克隆抗体,对30例死于转移性乳癌患者的尸解组织(平均每例2～5个转移灶组织)进行了回顾性检测研究。30例尸解组织标本中有8例呈现所有转移位点p185弥散性的强染色;5削弱染色;15例组织标本染色阴性,最后一例表现出混乱的染色:
HER-2/neu proto-oncogenes are amplified and overexpressed in 20% to 30% of invasive breast cancers. However, the study of HER-2/neu overexpressing changes and tumor progression or the heterogeneity of the expression of different metastatic sites is very limited, in order to determine whether the HER-2/neu protein content in the primary tumor is different from invasive cancer, invasive cancer. Whether HER-2/neu expression is heterogenous, the author used immunoperoxidase technology and anti-HER-2/neu gene 185-kD protein product (p185) monoclonal antibody, and 30 patients died of metastatic breast cancer The autopsy tissue (average of 2 to 5 metastases per case) was retrospectively tested. Eight of the 30 autopsy tissue samples showed diffuse staining of all metastatic sites p185; 5 weakened staining; 15 tissue specimens stained negative, and the last case showed confusing staining: